Safety and efficacy of granulocyte/monocyte apheresis in steroid-dependent active ulcerative colitis with insufficient response or intolerance to immunosuppressants and/or biologics (ART trial): 12-week interim results.

Axel Dignass ¹, Ayesha Akbar ², Ailsa Hart ², Sreedhar Subramanian ³, Gilles Bommelaer ⁴, Daniel C Baumgart ⁵, Jean-Charles Grimaud ⁶, Guillaume Cadiot ⁷, Richard Makins ⁸, Syed Hoque ⁹, Guillaume Bouguen ¹⁰, Bruno Bonaz ¹¹ , J Crohns Colitis. 2016 Jul;10(7):812-20. 

At Week 12, Adacolumn provided significant clinical benefit in a large cohort of steroid-dependent ulcerative colitis patients with previous failure to immunosuppressant and/or biologic treatment, with a favourable safety profile. These results are consistent with previous studies and support Adacolumn use in this difficult-to-treat patient subgroup.

https://pubmed.ncbi.nlm.nih.gov/26818659/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955912/pdf/jjw032.pdf